TheEdgeResearch
Home / Stocks / TDSGF

Telo Genomics Corp. (TDSGF)

OTC Healthcare Medical - Diagnostics & Research
$0.03 ▲ +0.00%
Market Cap
$2.5M
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
0.24
52-Wk Range
0.018-0.057
CEO
John Allen Farlinger
Country
CA
Currency
USD

Telo Genomics Corp. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $0.03, up 0.00% on the session, giving a market capitalisation of $2.5M. On trailing twelve-month figures it carries a trailing P/E of -1.74, a net margin of 0.0%. Its beta of 0.24 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.74
Price / Sales
0.00
Price / Book
-2.54
EV / EBITDA
-2.44
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-0.91
Current ratio
0.21
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
8
IPO date
2021-01-08
Headquarters
Toronto, ON, CA
About Telo Genomics Corp.

Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health conditions. The company's primary innovation is a sophisticated telomere analysis platform, which serves both to diagnose diseases and to forecast patient outcomes. This technology, often integrated with liquid biopsies, provides crucial insights for applications in both cancer and neurological illnesses. Their leading product, Telo-MM, is specifically designed to arm medical professionals with vital, actionable information for effectively managing Multiple Myeloma, a serious blood cancer. Additionally, Telo Genomics offers TeloView, a proprietary software system capable of precisely measuring individual patient telomere characteristics. Telo Genomics caters to a broad spectrum of clients, including diagnostic pathologists, clinical doctors, academic researchers, and pharmaceutical developers. A notable endorsement of its technology is a collaborative agreement with the renowned Mayo Clinic, aimed at validating the Telo-MM diagnostic tests for multiple myeloma. Founded in 2014 and based in Toronto, Canada, the company adopted its current name, Telo Genomics Corp., in April 2019, having previously operated as 3D Signatures Inc.

Comparable companies

Telo Genomics Corp. is most often compared with the following Healthcare names:

CLABFCTABFENZNHLYKICBUIDXGRNVARVVTFSLDXTGIFF
More research on TDSGF
TDSGF technical analysis TDSGF TheEdge Score Compare against peers
Open full interactive analysis & DCF →